Categories: News

Bellabeat Records 50,000 Preorders Of New Smart-Wearable Product, Ivy

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN FRANCISCO, Jan. 7, 2021 /PRNewswire-PRWeb/ — After selling 20,000 preorders in the first hour of its announcement, the leading wellness tech company Bellabeat has now already sold over 50,000 preorders of its new smart-wearable product, the Bellabeat Ivy. Ivy is a smart jewelry product for women and the successor of the Bellabeat Leaf, which was sold more than 2.2 million times to date.

Just like its predecessor, Ivy is a smart-wearable product designed specifically for women. It features enhanced sensors as well as tracking capabilities and provides data to help improve the general wellbeing, productivity, and reproductive health of its female wearers. With major upgrades to its overall quality and the technology it uses, Ivy still manages to be 30 percent lighter than the Leaf.

With up to 20 days of battery life, the beautiful bracelet tracks women’s respiratory rate, resting heart rate, heart rate variability (HRV), body temperature, light, deep, and REM sleep, as well as sleep timing and quality to provide a complete overview of their productivity, health, recovery, and wellbeing. Ivy is also water-resistant, fits any outfit, and is designed to be worn at all times. It can further be recharged within less than two hours.

Ivy continuously tracks movements, activity, and heart rate, which allows for reliable calculations of active calorie burn, and, by using Ivy regularly, women will also learn about their sleeping patterns with detailed information on different sleep phases, sleep duration, and sleep quality. The data Ivy provides enables women to see a detailed breakdown of their health and discover areas needing improvement in a newly developed mobile application.

“With Ivy, our team has developed a unique approach to women’s wellness powered by user data and its analysis through artificial intelligence,” says Melanie Messina, Head of Product at Bellabeat. “We are especially proud of the “Wellness Score,” which is estimated when correlating different lifestyle tracking data points, such as activity patterns, mindfulness habits, sleep habits, as well as hydration, and our “Readiness” scale, which is scored based on the bio-responses of the wearer,” Messina says.

Bellabeat aims to start shipping the first Ivy units by the end of January 2021. Pre-orders are currently closed, with a second pre-order campaign expected to launch within the next two weeks. For more information and a way to join the pre-order waiting list, visit https://bellabeat.com/ivy-preorder/.

Media Contact

Simon Moser, PolyGrowth, +31 644816790, simon@polygrowth.io

 

SOURCE Bellabeat

Staff

Recent Posts

FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance

Company to also highlight advancements in denials and underpayments management and speak to the measurable…

19 hours ago

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility…

19 hours ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…

22 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project as Federal Support for Blockchain Grows

Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and…

22 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs…

22 hours ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits…

22 hours ago